Back to Journals » Journal of Blood Medicine » Volume 10

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives

Authors Sarosiek S, Sanchorawala V

Received 19 September 2019

Accepted for publication 16 October 2019

Published 23 October 2019 Volume 2019:10 Pages 373—380

DOI https://doi.org/10.2147/JBM.S183857

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Martin H Bluth


Shayna Sarosiek, Vaishali Sanchorawala

Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

Correspondence: Shayna Sarosiek; Vaishali Sanchorawala
Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, 820 Harrison Ave, FGH Building – 1, Boston, MA 02118, USA
Tel +1617-637-7011
Fax +1617-414-1831
Email Shayna.Sarosiek@bmc.org; Vaishali.Sanchorawala@bmc.org

Abstract: Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the source of the amyloidogenic light chain. First-line therapies in this disease are well established, but in the relapsed or refractory setting, there are many treatment options, including immunomodulatory agents, proteasome inhibitors, alkylating agents, and monoclonal antibodies. Decisions regarding treatment choice should be made by a multidisciplinary team with consideration of the patient’s functional status, disease stage, degree of organ dysfunction, and potential treatment toxicities. Herein we review the current treatment options available for patients with relapsed or refractory AL amyloidosis.

Keywords: AL amyloidosis, light chain amyloidosis, relapsed, refractory

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]